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Aims: To assess the cardiovascular (CV) safety of oral semaglutide, the first tablet formulation
of a glucagon-like peptide-1 receptor agonist.
Materials and methods: PIONEER 6 is a multinational, randomized, placebo-controlled,
double-blind trial in patients with type 2 diabetes at high risk of CV events (defined as being
aged ≥50 years and having established CV disease [CVD] or moderate [stage 3] chronic kidney
disease [CKD], or being aged ≥60 years with ≥1 other CV risk factor). Patients were random-
ized to once-daily oral semaglutide (up to 14 mg) or placebo added to standard of care. The
primary composite endpoint is time to first occurrence of CV death or non-fatal myocardial
infarction or non-fatal stroke. The primary hypothesis was to exclude an excess in CV risk with
oral semaglutide by assessing non-inferiority versus placebo for the primary endpoint (non-
inferiority margin of 1.8 for the upper boundary of the 95% confidence interval of the hazard
ratio). PIONEER 6 is event-driven, with follow-up continuing until accrual of at least 122 pri-
mary outcome events. There is no pre-defined minimal duration.
Results: Overall, 3183 patients have been enrolled (mean age 66.1 years, 31.6% females) in
214 sites across 21 countries. At baseline, the mean duration of diabetes was 14.9 years,
mean glycated haemoglobin concentration was 66 mmol/mol (8.2%), and 84.6% of patients
had established CVD/moderate CKD.
Conclusions: PIONEER 6 will provide evidence regarding the CV safety of oral semaglutide in
patients with type 2 diabetes and high CV risk.
KEYWORDS
cardiovascular disease, cardiovascular outcomes trial, GLP-1 receptor agonist, oral
semaglutide, type 2 diabetes
1 | INTRODUCTION
Glucagon-like peptide-1 receptor agonists (GLP-1RAs) are glucose-
lowering agents recommended for the treatment of type 2 diabetes
that have been shown to lower glycated haemoglobin (HbA1c) levels
and body weight effectively, and are associated with a low risk of
hypoglycaemia and improved systolic blood pressure.1–4 Despite
these benefits, GLP-1RAs appear to be used less frequently than
other new glucose-lowering agents, such as dipeptidyl peptidase-4
inhibitors.5
An oral GLP-1RA formulation may improve acceptance and
adherence6 for some patients compared with injectable GLP-1RAs
and may lead to earlier initiation of GLP-1RA treatment in type 2 dia-
betes. However, successful delivery of peptides, such as GLP-1RAs,
through the oral route is challenging, because of numerous barriers to
absorption, including degradation by gastrointestinal enzymes, pH-
induced conformational changes and limited protein permeability of
the intestinal membrane.7,8
Semaglutide, a glucagon-like peptide-1 (GLP-1) analogue shown
to improve glycaemic control and reduce body weight when adminis-
tered subcutaneously (s.c.) in patients with type 2 diabetes9–11 and
recently approved for use in Europe,12 Canada,13 Japan14 and the
United States,15 is being developed as a once-daily oral tablet formu-
lation. Oral semaglutide is co-formulated with sodium N-(8-[2-hydro-
xybenzoyl] amino) caprylate (SNAC), an absorption enhancer that
promotes the absorption of semaglutide across the gastric mucosa via
effects on transcellular pathways.16
An oral formulation of semaglutide with similar efficacy and
safety to the s.c. formulation has the potential to increase the access
of GLP-1 therapies to patients with a preference for oral administra-
tion. In a 26-week, phase II trial conducted in 632 patients with type
2 diabetes and sub-optimal glycaemic control, oral semaglutide (doses
ranging from 2.5 to 40 mg once daily) reduced HbA1c levels com-
pared with placebo in a dose-dependent manner (−0.7% to −1.9%
compared with −0.3% with placebo).17 In the same trial, oral semaglu-
tide also demonstrated dose-dependent weight reduction (−2.1 to
−6.9 kg vs. −1.2 kg with placebo).17 The phase II study also compared
oral semaglutide with s.c. semaglutide 1 mg, with similar reductions in
HbA1c and comparable tolerability observed with higher doses of oral
semaglutide versus s.c. semaglutide.17 Based on a combined evalua-
tion of the efficacy and tolerability data in the phase II trial, three
doses of oral semaglutide (3, 7 and 14 mg once daily) were selected
for evaluation in the PIONEER (Peptide InnOvatioN for Early DiabEtes
TReatment) phase IIIa programme, which is ongoing to further investi-
gate the efficacy and safety of oral semaglutide in a large and broad
population of patients with type 2 diabetes.
Cardiovascular disease (CVD) is the leading cause of death in
patients with type 2 diabetes.18 Guidelines have been issued by regu-
latory authorities to the pharmaceutical industry regarding the evalua-
tion of cardiovascular (CV) safety to exclude an excess in CV risk with
new therapies to treat type 2 diabetes.19–21 In previous CV outcomes
trials, treatment with both s.c. liraglutide and s.c. semaglutide has
shown a CVD risk reduction compared with placebo in patients with
type 2 diabetes and high CV risk,22,23 with some guidelines
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recommending liraglutide for second-line use after metformin in these
patients.1 As part of the PIONEER programme, and in accordance with
regulatory guidance, PIONEER 6 is a pre-approval CV outcomes trial
that is being conducted to specifically explore CV safety of oral sema-
glutide compared with placebo. In the present paper, we describe the
design of the PIONEER 6 trial and report the baseline characteristics
of the trial population.
2 | METHODS
2.1 | Trial design and oversight
PIONEER 6 is an ongoing, randomized, double-blind, placebo-con-
trolled, parallel-group, international, multicentre CV outcomes trial to
compare the CV safety of oral semaglutide with placebo. PIONEER
6 is being conducted in 214 sites across 21 countries in Africa, Asia,
Europe, Latin America, North America and the Middle East. The trial is
registered with ClinicalTrials.gov (NCT02692716) and is being con-
ducted in compliance with International Conference on Harmonisation
Good Clinical Practice guidelines,24 applicable regulatory requirements
and in accordance with the Declaration of Helsinki.25
Approval by relevant local independent ethics committees and
institutional review boards, and national regulatory authorities was
mandated prior to the commencement of the trial at each site. All
patients provided written informed consent prior to any trial-related
activity.
A panel of lead principal investigators and selected trial coordina-
tors was nominated to provide advice on the conduct of the trial to
the sponsor. An independent data monitoring committee provides an
ongoing review of accumulating data and subsequent guidance on trial
continuation.
2.2 | Participants
Male and female patients diagnosed with type 2 diabetes were eligible
for inclusion in the trial if they were considered at high risk of CV
events, as defined by one the following two categories. (a) Presence
of established CVD or moderate (stage 3) chronic kidney disease
(CKD): age ≥50 years and established CVD (prior myocardial infarc-
tion [MI]; prior stroke or transient ischaemic attack; prior coronary,
carotid or peripheral arterial revascularization; >50% stenosis on angi-
ography or imaging of coronary, carotid or lower extremity arteries;
documented history of symptomatic coronary heart disease; docu-
mented asymptomatic cardiac ischaemia or chronic heart failure
(New York Heart Association [NYHA] class II–III); or moderate renal
impairment (estimated glomerular filtration rate [eGFR] 30–59 mL/
min/1.73 m2 using the Chronic Kidney Disease Epidemiology Collabo-
ration equation26). (b) CV risk factor(s) only (ie,. no prior CVD or mod-
erate CKD): age ≥60 years and the presence of at least one of the
following CV risk factors: microalbuminuria or proteinuria (diagnosed
according to local or commonly accepted guidelines); hypertension
and left ventricular hypertrophy (documented by ECG or imaging); left
ventricular systolic or diastolic dysfunction (by imaging); or ankle/bra-
chial index <0.9. Eligibility criteria were evaluated by the investigator
and clinical criteria were accordingly defined in line with local practice
and/or guidelines.
Following receipt of informed consent, a screening visit was com-
pleted during which patient demographics, medical history, concomi-
tant medications and concomitant illnesses were recorded, and a
physical examination was performed. Key criteria for exclusion from
the trial were: treatment with any GLP-1RA, dipeptidyl peptidase-4
inhibitor or pramlintide within 90 days prior to screening; NYHA class
IV heart failure; planned coronary, carotid or peripheral artery revas-
cularization; MI, stroke or hospitalization for unstable angina or tran-
sient ischaemic attack within 60 days prior to screening; history of
major surgical procedures involving the stomach that may affect drug
absorption; chronic/intermittent haemodialysis or peritoneal dialysis,
or severe renal impairment (eGFR <30 mL/min/1.73 m2); history of
diabetic ketoacidosis; and proliferative retinopathy or maculopathy
requiring acute treatment. Proliferative retinopathy or maculopathy
requiring acute treatment was verified by an eye examination (fundus
photography or dilated fundoscopy) performed within 90 days before
screening or during the screening period. Other exclusion criteria
were typical for a clinical trial in this patient population and are
detailed in the Supplementary Appendix.
2.3 | Trial treatment and procedures
Eligible patients were randomized in a 1:1 ratio to once-daily treat-
ment with either oral semaglutide or placebo (Figure 1), with randomi-
zation stratified based on evidence of established CVD/moderate
CKD at screening or CV risk factors only. Randomization could occur
on the same day as the screening visit or up to 3 weeks afterwards.
Randomization was performed using an interactive voice/web
response system (IV/WRS) and blinding of trial staff is maintained by
using the same IV/WRS for dispensing of trial drug and through the
use of visually identical oral semaglutide and placebo tablets in
identical packaging.
The dose for the evaluation of the CV safety of oral semaglutide
was 14 mg, which is the maximum dose chosen for study in the PIO-
NEER programme. To mitigate the potential for adverse gastrointesti-
nal events, patients followed a dose-escalation regimen receiving
3 mg oral semaglutide/placebo once daily for 4 weeks, followed by
7 mg oral semaglutide/placebo once daily for 4 weeks, and then
14 mg oral semaglutide/placebo once daily for the remainder of the
trial (Figure 1). Extensions of the dose-escalation period, dose reduc-
tions (and subsequent re-escalation) and treatment pauses (and subse-
quent re-initiation) were permitted during the trial if, based on the
investigator's opinion, unacceptable adverse events (AEs) occurred.
Patients were instructed to take the tablet in the morning in a fasting
state with up to half a glass of water (approximately 120 mL) and to
wait at least 30 minutes before eating, drinking or taking other oral
concomitant medication.
The study flow and visit schedule is presented in Figure 1 and
Supplementary Table 1. Trial visits occurred at weeks 2, 4 and 8
following randomization, and approximately every 6 or 7 weeks there-
after (Figure 1). A variety of assessments and procedures are per-
formed at different intervals (Supplementary Table 1), including vital
signs, body weight, ECG, blood sampling (for evaluation of HbA1c,
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fasting plasma glucose, lipids, biochemistry, haematology and calcito-
nin levels), assessment of trial treatment compliance and collection of
reports for serious AEs, AEs leading to discontinuation of trial treat-
ment and other events of special interest. In addition to the eye exam-
ination performed immediately before or as part of the screening
procedures, eye examinations are also being performed at around year
1 and at the end-of-treatment visit.
Investigators are responsible for the management of glycaemic
control in each patient. Background therapy with glucose-lowering
agents to maintain/optimize glycaemic control according to standard
of care in local or international guidelines is encouraged during the
trial at the investigator's discretion; however, the use of other
GLP-1RAs, dipeptidyl peptidase-4 inhibitors and pramlintide is not
permitted. Glycaemic management is guided by review of fasting
plasma glucose and HbA1c results from the trial site, and self-
measured blood glucose levels by the patient. Ongoing management
of CVD, risk factors and potential microvascular complications is con-
ducted by the investigators in accordance with local standards of care.
Investigators received written guidance to encourage them in main-
taining standard of care for the management of glycaemic control and
CV risk factors, including achievement of HbA1c ≤53 mmol/mol (7%)
(or individualized target, depending on the patient characteristics),
blood pressure targets of 140/90 mmHg (angiotensin-receptor
blockers or angiotensin-converting enzyme inhibitors are suggested as
first line, but other antihypertensive agents may be considered based
on individual patient needs; lower blood pressure targets may also be
considered as appropriate for some individuals), and treatment with
statins and aspirin as recommended.
2.4 | Endpoints and assessments
The primary endpoint is time from randomization to first occurrence
of a major adverse CV event (MACE) composite endpoint consisting
of CV death, non-fatal MI or non-fatal stroke (the classic three-point
MACE). Secondary endpoints include: time from randomization to first
occurrence of an expanded composite CV endpoint (encompassing
the same events as the primary endpoint, plus unstable angina requir-
ing hospitalization or hospitalization for heart failure); time from ran-
domization to first occurrence of the individual components of the
expanded composite CV endpoint; time to first occurrence of a
composite of all-cause death, non-fatal MI or non-fatal stroke; time to
all-cause death; time to permanent trial drug discontinuation due to
AEs; number of serious AEs; and changes from baseline in a variety of
laboratory and clinical assessments. CV events and other selected
types of events are adjudicated by an independent blinded external
event adjudication committee.
2.5 | Trial duration and follow-up
PIONEER 6 is an event-driven trial and will continue until at least
122 adjudication-confirmed first MACEs have occurred. There is no
pre-specified duration of exposure to trial medication and so it is likely
that there will be fewer primary endpoint events than seen in the sim-
ilar CV outcome trials for liraglutide and s.c. semaglutide.22,23 Follow-
up visits will be held 5 weeks after the end-of-treatment visit to allow
safety assessments after wash-out of the trial drug. Patients who dis-
continue trial drug prematurely will continue to be followed in accor-
dance with the planned visit schedule. No interim analyses are
planned, other than those conducted by an independent data moni-
toring committee.
2.6 | Statistical methods
The trial aims to confirm that treatment with oral semaglutide does
not result in an unacceptable increase in CV risk compared with pla-
cebo (upper limit of the two-sided 95% confidence interval [CI] does
not exceed 1.8) in patients with type 2 diabetes and at high CV risk.
This is in line with the US Food and Drug Administration (FDA) guid-
ance for approval of new glucose-lowering agents in type 2 diabetes.21
Analysis of the primary endpoint (time from randomization to first
MACE) will include all of the first MACEs occurring during the trial
from randomization to the patient's last visit (at follow-up approxi-
mately 5 weeks after the last planned dose of the trial product),
regardless of adherence to trial treatment and procedures or adjust-
ment of background medication. A stratified Cox proportional hazards
model will be used for the primary analysis, with treatment group as a
fixed factor, and stratification based on evidence of CVD or advanced
CKD at screening. Estimated hazard ratio and the two-sided 95% CI
will be determined, with non-inferiority confirmed in accordance with
FDA guidance, as outlined earlier.21 If non-inferiority is confirmed, a
test for superiority versus placebo will be performed, thereby preserv-
ing the type 1 error in the strong sense at 5% (two-sided) when using
the hierarchical testing strategy. Sensitivity analyses will explore
the robustness of the primary analysis. All primary and secondary ana-
lyses will be performed on the full analysis set, which will include all
FIGURE 1 Trial design. MACE, major adverse cardiovascular event
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randomized patients. According to the study protocol, no interim ana-
lyses are planned before the database is locked.
2.7 | Sample size
A log-rank test determined that to confirm non-inferiority for the pri-
mary endpoint with 90% power, a total of 122 first MACEs are
required. Based on the anticipated event rate and chosen sample size,
it is estimated that the treatment period for each patient will be
between 12 and 19 months, depending on recruitment time and
accrual rate of first MACEs. For a total of 122 first MACEs to occur
within a trial duration of approximately 19 months (including an
expected 7-month recruitment period), we calculated that 3176
patients would require randomization. The sample size calculation was
guided by assumptions derived from data from the LEADER and SUS-
TAIN 6 CV outcomes trials,22,23 including an anticipated first MACE
rate of 3 per 100 patient years across both treatment groups and a
loss-to-follow-up rate of 1% per year. A maximum of 650 patients
(approximately 20%) was permitted within the CV risk factors only
stratum to ensure sufficient CV risk within the trial population to
accrue the sufficient number of events.
3 | RESULTS
The first patient was randomized on 17th January 2017 and recruit-
ment was completed on 29th August 2017, representing a recruit-
ment period of just over 7 months. In total, 3418 patients underwent
screening, with 3183 randomized to treatment. The majority of
patients (84.6%) were aged ≥50 years and had established CVD or
moderate CKD, while the remainder (15.4%) were aged ≥60 years
with the presence of CV risk factors only.
The baseline characteristics of the enrolled patients were com-
piled in a blinded manner after completion of enrolment and before
data cleaning. One third of the randomized patients were female
(31.6%) and the mean age at baseline was 66.1 years (Table 1). The
mean body mass index was 32.3 kg/m2. The majority of participants
were white (72.3%). The average duration of diabetes at baseline was
14.9 years, and the most frequently used glucose-lowering agents
were biguanides (metformin; 76.6% of patients), insulin (61.0%), sul-
phonylureas (31.6%) and sodium-glucose co-transporter-2 (SGLT2)
inhibitors (9.5%; Table 1). The mean HbA1c level was 66 mmol/mol
(8.2%). The mean eGFR was 74.2 mL/min/1.73 m2 and just over one
quarter of patients (26.2%) had an eGFR <60 mL/min/1.73 m2.
Approximately one third of patients were reported by the investiga-
tors as having diabetic nephropathy (33.5%), with diabetic retinopathy
and neuropathy also reported to be present in 27.2% and 36.0% of
patients, respectively.
The mean baseline blood pressure was 136/76 mm Hg, and the
mean fasting lipid levels were as follows: low-density lipoprotein
(LDL) cholesterol, 2.2 mmol/L; high-density lipoprotein (HDL) choles-
terol, 1.1 mmol/L; and triglycerides, 2.0 mmol/L. The majority of
patients were treated with antihypertensive drugs (95.3%), lipid-
lowering therapies (86.4%), and antithrombotic (antiplatelet and/or
anticoagulant) medication (79.0%).
TABLE 1 Demographics and baseline characteristics
Total randomized
population (N = 3,183)
Female, n (%) 1007 (31.6)
Age, ys 66.1 (7.1)
≥65 ys, n (%) 1848 (58.1)
≥75 ys, n (%) 410 (12.9)
Race, n (%)
American Indian or Alaska Native 29 (0.9)
Asian 630 (19.8)
Black or African American 192 (6.0)
Native Hawaiian or other Pacific Islander 6 (0.2)
Other 26 (0.8)
White 2300 (72.3)
Ethnicity, n (%)
Hispanic or Latino 514 (16.1)
Body weight, kg 90.9 (21.2)
Body mass index, kg/m2 32.3 (6.5)
HbA1c, mmol/mol 66 (18)
HbA1c, % 8.2 (1.6)
Fasting plasma glucose, mmol/L 8.7 (3.3)
Diabetes duration, ys 14.9 (8.5)
Glucose-lowering medication, n (%)
Insulin 1943 (61.0)
Biguanides 2437 (76.6)
SGLT2 inhibitors 301 (9.5)
Sulphonylureas 1007 (31.6)
Other 264 (8.3)
CVD status, n (%)
Established CVD 2692 (84.6)
CV risk factors only 491 (15.4)
Antihypertensive medication, n (%) 3034 (95.3)
Lipid-lowering medication, n (%) 2750 (86.4)
Antithrombotic medication, n (%) 2516 (79.0)
Smoking history, n (%)
Current 348 (10.9)
Previous 1399 (44.0)
Never 1436 (45.1)
Investigator-reported microvascular complications, n (%)
Diabetic retinopathy 866 (27.2)
Diabetic nephropathy 1066 (33.5)
Diabetic neuropathy 1145 (36.0)
eGFR,a mL/min/1.73 m2, Mean (SD) 74.2 (21.0)
<30 mL/min/1.73 m2, n (%) 29 (0.9)
≥30 to <60 mL/min/1.73 m2, n (%) 827 (26.1)
≥60 to <90 mL/min/1.73 m2, n (%) 1389 (43.9)
≥90 mL/min/1.73 m2, n (%) 918 (29.0)
Vital signs
Systolic blood pressure, mmHg 135.6 (17.6)
Diastolic blood pressure, mmHg 76.0 (10.1)
Cholesterol
LDL cholesterol, mmol/L 2.2 (0.9)
HDL cholesterol, mmol/L 1.1 (0.3)
Triglycerides, mmol/L 2.0 (1.5)
Abbreviations: CV, cardiovascular; CVD, cardiovascular disease; eGFR,
estimated glomerular filtration rate; HbA1c, glycated haemoglobin; SGLT2,
sodium-glucose co-transporter-2.
Data are mean (SD) unless otherwise indicated.
a eGFR assessed using Chronic Kidney Disease Epidemiology Collabora-
tion formula in serum at baseline.
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4 | DISCUSSION
Four CV outcomes trials of GLP-1RAs have been published as of June
2018: ELIXA (once-daily s.c. lixisenatide),27 LEADER (once-daily
s.c. liraglutide),22 SUSTAIN 6 (once-weekly s.c. semaglutide)23 and
EXSCEL (once-weekly extended-release s.c. exenatide28; Table 2). In
all four trials, CV safety was demonstrated for the GLP-1RA versus
placebo.22,23,27,28 Moreover, s.c. liraglutide and s.c. semaglutide
showed significant reductions in the classic three-point MACE end-
point versus placebo (hazard ratios 0.87 [95% CI 0.78, 0.97] and 0.74
[95% CI 0.58, 0.95], respectively)22,23 and a recent meta-analysis has
reported a significant 10% relative risk reduction in the classic three-
point MACE endpoint with GLP-1RAs versus placebo.36
The mechanism whereby GLP-1RAs may reduce CV risk is not fully
elucidated. Preclinical studies suggest various potential mechanisms for
the CV benefit of these agents.37 in vitro studies suggest these agents
may have effects on adhesion molecules and endothelial function that
may inhibit atherosclerosis and thrombosis.38 A randomized trial in
patients with newly diagnosed and treatment-naïve type 2 diabetes
found that six months of liraglutide treatment improved arterial stiffness
and left ventricular myocardial strain, and reduced N-terminal pro b-type
natriuretic peptide independently of weight loss by reducing oxidative
stress.39 A meta-analysis in patients with type 2 diabetes has also
indicated that GLP-1-based therapy is associated with an increase in
flow-mediated dilation, reductions in atherosclerotic markers such as C-
reactive protein, plasminogen activator inhibitor-1 and B-type natriuretic
peptide, as well as reductions in LDL cholesterol and triglycerides.40
The PIONEER 6 study will add to this evidence base for the CV
safety of GLP-1RAs and uses the same primary endpoint as SUSTAIN-
6. To rule out an unacceptable increase in CV risk caused by oral
semaglutide, and in line with FDA guidance,21 PIONEER 6 enrolled a
population of patients with type 2 diabetes at high risk of CV events.
The eligibility criteria are similar to those of the CV outcomes trial
with once-weekly s.c. semaglutide (SUSTAIN 6),23 the same molecular
entity in a different formulation, including patients with established
CVD/moderate CKD, and also some with well-established CV risk fac-
tors and advanced age. Such a population at elevated risk of CV
events was selected to ensure accruing of events so that the primary
objective of the trial could be reached within a reasonable timeframe.
Similarly to SUSTAIN 6, the majority (>80%) of patients recruited in
PIONEER 6 had prior CVD/moderate CKD, with less than one sixth of
participants having only CV risk factors (Table 2). Moreover, the pres-
ence of CV risk factors and use of CV medications was similar in PIO-
NEER 6 compared with SUSTAIN 6 (Table S2). Compared with
SUSTAIN 6, PIONEER 6 included a greater proportion of patients
receiving SGLT-2 inhibitors (0.2% vs. 9.5%),23 reflecting the increasing
use of this drug class. In contrast to SUSTAIN 6,23 there was no lower
threshold for HbA1c in PIONEER 6, which could explain why baseline
HbA1c was lower (66 mmol/mol [8.2%]) than in the LEADER and
SUSTAIN 6 studies (72 mmol/mol [8.7%] for both).22,23
The populations of PIONEER 6 and SUSTAIN 623 are very similar
to that used in LEADER,22 but differ from that studied in the ELIXA
CV outcomes trial with once-daily s.c. lixisenatide, which included
only patients with type 2 diabetes and acute coronary syndrome
within the previous 180 days (Table 2).27 The EXSCEL CV outcomes
trial with once-weekly exenatide included a patient population with a
slightly wider range of CV risk, with ~73% of the population having
prior CVD.28,31 As opposed to the other GLP-1RA trials, the ongoing
REWIND CV outcomes trial with once-weekly dulaglutide includes a
markedly lower proportion of patients with established CVD (31% in
REWIND vs. 85% in PIONEER 6), a higher proportion of females
(46.3% in REWIND vs. 31.6% in PIONEER 6), a lower mean HbA1c
(56 mmol/mol [7.3%] in REWIND vs. 66 mmol/mol [8.2%] in PIONEER
6) and a longer trial duration (7–8 years).33 The differences in patient
populations and trial design from various GLP-1RA CV outcomes trials
indicate that care should be taken when comparing outcomes between
trials or generalizing data to a broader diabetes population.
Time from randomization to the three-point MACE composite
endpoint (CV death, non-fatal MI or non-fatal stroke) was selected as
the primary endpoint of PIONEER 6, an approach that captures the
three CV events mandated by the FDA for such trials21 and is consis-
tent with most recent CV outcomes trials with GLP-1RAs (Table 2).19
Although PIONEER 6 has recruited a similar high CV risk patient pop-
ulation to those included in other recent CV outcomes trials in diabe-
tes and includes a similar primary endpoint, differences in trial design
will influence interpretation of the final data. PIONEER 6 is powered
as a non-inferiority trial to exclude an unacceptable increase in CV risk
compared with placebo, as set by the FDA (upper limit of the 95% CI
below 1.8). PIONEER 6 is solely event-driven (close down of the trial
will be initiated once the estimated number of first MACEs [n = 122]
needed to rule out an excess risk have been accrued) and does not
include a minimum trial duration. PIONEER 6 will therefore accrue
substantially fewer CV events and have a shorter treatment duration
than other diabetes treatment CV outcomes trials, such as SUSTAIN
6 and LEADER, which had a minimum trial duration after the last
patient was randomized (the median observation time in SUSTAIN
6 and LEADER was 2.1 and 3.8 years respectively [Table 2]).19,22,23 In
both the LEADER and SUSTAIN 6 trials, more endpoint events were
accrued (approximately double) than the number needed to achieve
statistical power,22,23 as a result of the minimum duration and higher
than expected event rates. The accrual of more events in SUSTAIN
6 allowed that trial to identify a significantly lower risk of the primary
outcome (albeit not pre-specified before trial initiation) of three-point
MACE among patients treated with s.c. semaglutide compared with
placebo (P = 0.02 for superiority of s.c. semaglutide).23 It has been
suggested that trial duration is a factor in being able to demonstrate
CV risk reductions in diabetes CV outcomes trials.39 Nevertheless, a
relatively short trial duration was used for PIONEER 6 to allow the CV
safety of oral semaglutide to be determined early in the development
programme and because the CV safety of semaglutide as a
s.c. formulation had already been demonstrated in SUSTAIN 6; how-
ever, due to the short duration and expected accrual of fewer events
than SUSTAIN 6, a statistically significant CV risk reduction with oral
semaglutide versus placebo may be less likely.
5 | CONCLUSION
In summary, PIONEER 6 is a pre-approval non-inferiority trial that will
investigate the CV safety of oral semaglutide compared with placebo
and will, therefore, provide an important insight for regulatory
approval. The trial has completed enrolment of 3183 patients with
6 BAIN ET AL.
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type 2 diabetes who are at high CV risk and will conclude once a mini-
mum of 122 adjudication-confirmed first MACEs needed to determine
CV safety are accrued.
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